Albumin/Creatinine Ratio Normal Range and Why It Matters

An albumin-to-creatinine ratio (ACR) below 30 mg/g in a spot urine sample is generally classified as normal, meaning the kidneys are not leaking significant amounts of the protein albumin into the urine. Values of 30 to 300 mg/g signal moderately increased albuminuria, and anything above 300 mg/g indicates severely increased albuminuria. Those thresholds sound tidy, but newer research has complicated them: even values well within the “normal” range, particularly between 10 and 30 mg/g, carry measurably higher risks for cardiovascular disease and death in certain populations.

What the Test Actually Measures

Albumin is a protein your liver makes in large quantities. Healthy kidneys keep virtually all of it in the bloodstream, filtering waste while holding onto useful molecules. When the tiny filters inside your kidneys (the glomeruli) become damaged, albumin starts slipping through into the urine. The ACR compares the amount of albumin in a urine sample against the amount of creatinine, a waste product your muscles produce at a fairly steady rate. Dividing albumin by creatinine adjusts for how concentrated or dilute the urine happens to be at the moment you gave the sample, giving clinicians a snapshot that roughly mirrors what a full 24-hour urine collection would show.

This matters because a single raw albumin measurement can swing wildly depending on how much water you drank that morning. The creatinine correction is what makes a random spot sample clinically useful. Most guidelines now recommend a first-morning urine sample rather than a random one collected at any time of day, because morning samples tend to be more consistent. A study using data from a large U.S. health survey found that the estimated prevalence of increased ACR was about 15% when based on a random spot sample but dropped to roughly 13% with a first-morning sample, and fell further to about 12% when two samples taken within ten days both had to confirm the result.¹ That difference shows why a single random test can overestimate the problem, and why doctors often ask for a repeat sample before labeling someone with chronic kidney disease.

The Standard Categories

The widely used classification system comes from the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, which recommend staging chronic kidney disease based on both kidney filtration rate and albuminuria level.² The albuminuria categories are:

A1 (normal to mildly increased): ACR below 30 mg/g. Most healthy adults fall here.
A2 (moderately increased): ACR of 30 to 300 mg/g. Historically called “microalbuminuria,” this range signals early kidney damage.
A3 (severely increased): ACR above 300 mg/g. Historically called “macroalbuminuria,” this indicates substantial protein leakage and more advanced disease.

These tiers feed into a color-coded risk grid that combines albuminuria stage with estimated glomerular filtration rate (eGFR) to predict how likely kidney function is to decline, and how high the risk of cardiovascular events and death may be. Someone with mildly reduced filtration and an ACR in the A1 range sits in a green “low risk” zone, while someone with the same filtration rate but an ACR above 300 mg/g is in an orange or red “very high risk” zone. Japanese population data has confirmed that this heat-map approach tracks real-world outcomes for cardiovascular events, kidney failure, and death.³

Why “Normal” May Not Mean Safe

One of the more striking findings in recent years is that the risk associated with albumin leakage does not begin neatly at 30 mg/g. A nationwide cohort analysis of people with hypertension found that even mildly elevated ACR values of 10 to 30 mg/g, still within the conventional normal range, were associated with significantly increased mortality.⁴ In other words, there appears to be no clean threshold below which albumin in the urine is entirely harmless. Risk rises on a gradient.

The mechanism behind this likely involves the blood-vessel lining throughout the body, not just in the kidneys. Research has suggested that the increased permeability of kidney blood vessels that lets albumin through may reflect broader endothelial dysfunction, meaning the inner lining of blood vessels everywhere is subtly impaired. This vascular leakiness has been linked to changes in clotting factors and inflammatory markers that raise cardiovascular risk.⁵ So the ACR is not purely a kidney test. It can function as a window into vascular health more broadly, which is why cardiologists pay attention to it too.

The Diabetes Connection

Diabetes is the most common reason doctors order an ACR test in the first place. Persistently high blood sugar damages the delicate filtering structures in the kidneys over time, and rising albumin in the urine is often the first detectable sign. This condition, diabetic nephropathy, progresses through a pattern: first the ACR creeps above 30, then it climbs further, and eventually kidney filtration itself starts to decline. Research has shown a positive correlation between the ACR and other markers of early kidney damage in people with diabetes, reinforcing its value as an early warning system.⁶

Current guidelines recommend that people with type 2 diabetes get their ACR checked at least once a year starting at diagnosis, and people with type 1 diabetes starting about five years after diagnosis. This annual screening is one of the most straightforward things you can do to catch kidney problems early enough to slow or stop them. The frustrating reality is that many people with diabetes are never screened at all, or only tested sporadically, which means kidney damage can accumulate silently for years before anyone notices.

Cardiovascular Risk Beyond the Kidneys

For people with high blood pressure, an elevated ACR carries its own prognostic weight even when kidney function by filtration rate looks fine. The ACR is considered a well-established, noninvasive biomarker of glomerular injury and endothelial dysfunction.⁴ This means a high ACR in someone with hypertension can indicate that the blood pressure is already causing organ damage, even if the person feels fine. It can also help clinicians decide how aggressively to treat blood pressure or whether to add kidney-protective medications.

The cardiovascular angle is where this biomarker’s clinical utility keeps expanding. The ACR is increasingly used not just to identify kidney disease, but to stratify overall cardiovascular risk, particularly in people who already have diabetes or high blood pressure. A person with borderline blood pressure and an ACR of 50 mg/g may warrant earlier and more aggressive treatment than the same person with an ACR of 5.

Dipstick Tests Miss a Lot

If you have ever had a urine test at a routine checkup, odds are it was a dipstick, not a formal ACR. Dipstick tests are cheap and fast, but they are poor at detecting the early and moderate stages of albuminuria that matter most for prevention. One population-based study found that the dipstick had a sensitivity of only about 44% for detecting ACR values of 30 mg/g or above, meaning it missed more than half of the people with moderately increased albuminuria.⁷ Specificity was high, so a positive dipstick usually means something real, but a negative one is far from reassuring.

Another study found somewhat better sensitivity when including “trace” results as positive, pushing detection of ACR at or above 30 mg/g up to about 69%, but this came at the cost of lower specificity and more false alarms.⁸ The dipstick performs much better at catching severely increased albuminuria above 300 mg/g, where sensitivity reaches nearly 100%. The practical takeaway: if you are at risk for kidney disease because of diabetes, hypertension, or a family history, a normal dipstick does not rule out early kidney damage. Ask specifically for an ACR test.

Things That Temporarily Spike Your ACR

A single elevated ACR does not necessarily mean your kidneys are damaged. Several transient factors can push albumin into the urine for a short time. Vigorous exercise in the previous 24 to 48 hours is a classic one; intense physical activity temporarily increases glomerular permeability. Fever and active infections can do the same. Menstruation can contaminate a urine sample with blood proteins. Poorly controlled blood sugar in a diabetic person can cause a temporary spike that may not reflect permanent kidney changes. Dehydration concentrates the urine and can make the ratio look worse than it is, though the creatinine correction is supposed to mitigate this.

This is exactly why guidelines call for confirmation with a second sample before diagnosing someone with chronic kidney disease. As the NHANES data showed, requiring confirmation from two separate samples drops the estimated prevalence by several percentage points.¹ If your doctor tells you your ACR came back elevated, the right response is usually to retest under better conditions before concluding anything.

Lowering an Elevated ACR Through Diet

Salt restriction is one of the most effective lifestyle changes for reducing albuminuria, and the evidence here is solid. A meta-analysis found that cutting sodium intake by an average of about 92 mmol per day (roughly equivalent to reducing salt by about 2 grams per day) was associated with about a 32% reduction in urinary albumin excretion.⁹ The effect was even larger in people already taking blood pressure medications that block the renin-angiotensin system, and in those with existing kidney damage.

A clinical trial confirmed this interaction in practice: patients with hypertension who received intensive education on following a low-salt diet showed dramatically greater decreases in albumin excretion compared to a control group, with a clear correlation between how much they reduced their sodium intake and how much their albuminuria improved.¹⁰ This is worth emphasizing because many people on blood pressure medication assume the drug alone is handling the problem. The evidence says diet and medication work best together for protecting the kidneys.

Beyond sodium, maintaining a healthy weight, controlling blood sugar if you have diabetes, and avoiding excessive protein intake all play supporting roles. Regular moderate exercise helps blood pressure and metabolic health, though as mentioned, very intense exercise right before a test can actually spike your ACR temporarily.

Medications That Bring Down the Number

Two families of blood pressure medications are considered first-line for reducing albuminuria: ACE inhibitors and angiotensin receptor blockers (ARBs). Both work by relaxing pressure inside the kidney’s filtering units, which reduces how much albumin gets pushed through damaged membranes. A meta-analysis of randomized trials in people with primary hypertension found that both drug classes effectively reduced urinary protein levels, with no significant difference between them.¹¹ The choice between the two usually comes down to side effects and individual tolerance rather than kidney-protective superiority.

More recently, SGLT2 inhibitors (originally developed as diabetes drugs) have shown substantial kidney-protective effects that go beyond blood sugar control. These medications reduce albuminuria and slow the progression of chronic kidney disease even in people without diabetes, and they have become a standard part of kidney-protective treatment in many guidelines. GLP-1 receptor agonists, another class of diabetes medications, have also shown benefits for kidney outcomes.

The newest addition is finerenone, a nonsteroidal mineralocorticoid receptor antagonist. In a real-world study of people with type 2 diabetes and chronic kidney disease who were already taking SGLT2 inhibitors and GLP-1 receptor agonists, adding finerenone produced a median reduction in ACR of about 51% over roughly 27 weeks of follow-up.¹² That is a large drop, and it held across different subgroups. The tradeoff is that finerenone raises potassium levels, which means regular blood monitoring is necessary. Still, the ability to stack three different kidney-protective drug classes represents a real shift in how aggressively albuminuria can now be treated in high-risk patients.

Who Should Be Screened and How Often

People with diabetes and those with hypertension are the clearest candidates for regular ACR testing, and most guidelines recommend annual screening for these groups. But the question of whether to screen the broader population is more nuanced. A cost-effectiveness analysis published in the Annals of Internal Medicine found that a one-time screening for chronic kidney disease at age 55 was cost-effective, and that screening once between ages 35 and 75 could prevent dialysis or transplant in hundreds of thousands of people.¹³ Repeated screening every ten years until age 75 also came in under the commonly used cost-effectiveness threshold.

The argument for broader screening rests on the fact that chronic kidney disease is extremely common, often silent until advanced stages, and increasingly treatable when caught early. The argument against it focuses on the risk of overdiagnosis and anxiety from false positives, though the confirmation-testing approach discussed earlier helps mitigate that. If you are over 50 and have never had an ACR test, it is reasonable to ask your doctor whether one makes sense even if you do not have diabetes or high blood pressure, particularly if you have a family history of kidney disease, are of African or South Asian descent, or have had cardiovascular events.

ACR Testing in Children

The standard adult cutoff of 30 mg/g does not apply cleanly to children. A study of children in southwest China found that ACR values were inversely correlated with age, meaning younger children naturally have higher ratios that decline as they grow.¹⁴ The same study found that higher body mass index and higher blood pressure were associated with higher ACR values even in childhood. These findings mean that pediatric ACR results need age- and sex-specific reference ranges rather than a one-size-fits-all threshold. A value that would be normal in a four-year-old might be flagged in a teenager, and vice versa. If your child has an ACR test, make sure the interpretation accounts for their age.

Point-of-Care Devices and Home Monitoring

Traditional ACR testing requires sending a urine sample to a laboratory, which introduces delays and adds cost. Newer point-of-care devices aim to change that by providing results at the bedside or even at home. One such device showed excellent agreement with the standard laboratory method across 103 samples from high-risk patients, with near-perfect sensitivity and specificity for detecting severely increased albuminuria and strong overall correlation with reference values.¹⁵ The device also included wireless data transmission, meaning results could flow directly into a patient’s medical record.

This kind of technology could be a game-changer for the millions of people with diabetes or hypertension who need regular ACR monitoring. Instead of scheduling a lab visit, a person could test at home the way they already check blood sugar, and share the results with their doctor remotely. We are not quite there yet for widespread consumer use, but the accuracy data is encouraging, and several companies are working toward regulatory approval for home-use versions. For people in rural areas or those who struggle with frequent medical appointments, accessible ACR monitoring could mean catching kidney deterioration months or years earlier than the current system manages.